Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Electrochemical reduction for chlorinated hydrocarbons contaminated groundwater remediation: Mechanisms, challenges, and perspectives.
Water Res
January 2025
State Key Laboratory of Geohazard Prevention and Geoenvironment Protection (Chengdu University of Technology), 1#, Dongsanlu, Erxianqiao, Chengdu 610059, Sichuan, PR China; State Environmental Protection Key Laboratory of Synergetic Control and Joint Remediation for Soil & Water Pollution (Chengdu University of Technology), 1#, Dongsanlu, Erxianqiao, Chengdu 610059, Sichuan, PR China. Electronic address:
Electrochemical reduction technology is a promising method for addressing the persistent contamination of groundwater by chlorinated hydrocarbons. Current research shows that electrochemical reductive dechlorination primarily relies on direct electron transfer (DET) and active hydrogen (H) mediated indirect electron transfer processes, thereby achieving efficient dechlorination and detoxification. This paper explores the influence of the molecular charge structure of chlorinated hydrocarbons, including chlorolefin, chloroalkanes, chlorinated aromatic hydrocarbons, and chloro-carboxylic acid, on reductive dechlorination from the perspective of molecular electrostatic potential and local electron affinity.
View Article and Find Full Text PDFEffectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Medicine (Baltimore)
January 2025
Department of Hepatobiliary Surgery, The Third Central Hospital of Tianjin, Tianjin, China.
Background: In patients with advanced hepatocellular carcinoma (HCC) following sorafenib failure, regorafenib has been used as an initial second-line drug. It is unclear the real efficacy and safety of sorafenib-regorafenib sequential therapy compared to placebo or other treatment (cabozantinib or nivolumab or placebo) in advanced HCC.
Methods: Four electronic databases (PubMed, Embase, Web of Science, and Ovid) were systematically searched for eligible articles from their inception to July, 2024.
Superconductor-Insulator Transition Induced by Precise Subtripled Vapor Chemical Gating.
J Am Chem Soc
January 2025
State Key Laboratory of Precision and Intelligent Chemistry, CAS Key Laboratory of Mechanical Behavior and Design of Materials, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.
Recent progress in superconductor-insulator transition has shed light on the intermediate metallic state with unique electronic inhomogeneity. The microscopic model, suggesting that carrier spatial distribution plays a decisive role in the intermediate state, has been instrumental in understanding the quantum transition. However, the narrow carrier density window in which the intermediate state exists necessitates precise control of the gate dielectric layer, presenting a challenge to in situ map the carrier spatial distribution.
View Article and Find Full Text PDFDelta-Radiomics Using Machine Learning Classifiers With Auxiliary Data Sets to Predict Disease Progression During Magnetic Resonance-Guided Radiotherapy in Adrenal Metastases.
JCO Clin Cancer Inform
January 2025
Machine Learning Department, H. Lee Moffit Cancer Center and Research Institute, Tampa, FL.
Purpose: Adaptive radiotherapy accounts for interfractional anatomic changes. We hypothesize that changes in the gross tumor volumes identified during daily scans could be analyzed using delta-radiomics to predict disease progression events. We evaluated whether an auxiliary data set could improve prediction performance.
View Article and Find Full Text PDFPertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.
J Clin Oncol
January 2025
Breast Surgery, Kyoto University Graduate School of Medicine, Shogoin Sakyo-ku, Kyoto, Japan.
In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!